x min read

Propanc Biopharma Inc (OTCMKTS:PPCB) Is Today's Cancer Focus

Propanc Biopharma Inc (OTCMKTS:PPCB) Is Today's Cancer Focus
Written by
Jarrod Wesson
Published on
July 4, 2017
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Propanc Biopharma Inc (OTCMKTS:PPCB) put out that it had received Orphan Drug Designation (ODD) from the FDA for the use of PRP. The product is intended to provide treatment for pancreatic cancer by using a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. In addition, new information was provided about the progress of the R&D activities of the company in an update, which we will discuss in this article. But, before we explain anything about the business of PPCB, have a look at the most recent price action. SourcePropanc BiopharmaThe company was originally founded on October 15, 2007. It is headquartered in Melbourne, Australia. In the company documents, the following business objective is noted:

"The development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading" Source

The most relevant product candidate, PRP, is "an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically". It is still in a preclinical phase.Recent DevelopmentsOn June 26, 2017, it was put out that the company had received the Orphan Drug Designation from the FDA for the use of PRP. The announcement was quite relevant since the disease is very serious.

"The approved indication is one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of less than 5%. The lethal nature of this disease stems from its propensity to rapidly disseminate to the lymphatic system and distant organs, and is a major unmet medical issue." Source

The CEO celebrated the news and noted that the company is preparing for the next step, and trying the treatment in humans.

"We are now firmly focused on the hard work ahead of us to proceed into First-In-Human studies as soon as possible. Receiving ODD from the FDA provides us with tremendous confidence we are on the right path, and the potential benefits to fast track the development process and receive attractive benefits for up to seven years when we achieve market approval, is very exciting for an emerging biopharmaceutical company like ours. I am truly grateful to our shareholders who continue to support our company. I hope this encourages investors to see the true value of our technology." Source

What does the Orphan Drug Designation mean? It is a distinction that may be given to companies researching treatments for diseases affecting less than 200,000 American citizens. It is great news, not only because diagnostic agents from outside the company accepted the treatment, but also because the company will receive "tax credits of up to 50% of R&D costs, R&D grants, waived FDA fees and protocol assistance".Furthermore, on June 9, 2017, the company put out new progress in yet another Patent Cooperation Treaty patent application within its intellectual property portfolio. PRP received a "written opinion from an International Search Authority", wherein it noted the novelty, inventive step, and industrial applicability of the invention claimed in the application. Furthermore, in the press release, we could read that the experimental data found in the application, which was filed in April, 2017, "adequately supports the pending claims." James Nathanielsz, Propanc Biopharma's CEO, explained in the following words:

"We continue to make significant progress with our IP portfolio and look forward to entering the national phase where we will seek to obtain jurisdiction in key countries and regions, globally" Source

Regarding other investment assessments found about the company, SeeThruEquity issued an update, wherein we could read that the target price given is $5.10. The reasons were specified in the report:

"We are updating our price target to $5.10 for PPCH following the completion of several corporate events, including a reverse share split, recent results, and the company's move towards its first in-human clinical trial." Source

ConclusionPropanc put out recently that it had received the Orphan Drug Designation from the FDA, which means not only recognition but also tax credits for the company. Additionally, it was put out that another International Search Authority had given a written opinion about PRP. Finally, we checked the independent equity research firms' assessment on the company and found out that SeeThruEquity gave a price target of $5.10. The share price at the moment is $0.97. To sum up, there's a lot to like about PPCB. It's only a matter of time before the company releases major PRP news that will really drive the share price.We will be updating our subscribers as soon as we know more. For the latest updates on PPCB, sign up below!Image courtesy of FlickrDisclosure: We have no position in PPCB and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.